With these words Josep Samitier inaugurated last week the tribute event to Josep A. Planell, one of the founders and first director of IBEC, for a whole life dedicated to … Read more
Fiona Watt, Director of the Centre for Stem Cells & Regenerative Medicine at King’s College London, and member of IBEC´s International Scientific Committee (ISC), has been appointed as new Director of the European Molecular Biology Organization (EMBO). The British cell biologist will take up the appointment in early 2022.
The Mayor of Barcelona, Ada Colau, visited IBEC facilities last Friday to learn, by our Director and a group of researchers, how bioengineering can help find solutions to health problems such as COVID19, cancer, or degenerative diseases.
When in early 2020, more than 200 scientists gathered in La Pedrera in Barcelona to discuss the present and future of bioengineering, no one imagined that the world would experience the first pandemic of the 21st century and that science would take on more importance than ever.
IBEC researchers led by ICREA Research Professor Núria Montserrat, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origin of the Coronavirus 2019 disease.
The treatment, which can be tested on two hundred Covid-19 patients as of today, has proven effective in mini-kidneys generated from human stem cells. Using hese organoids generated by bioengineering techniques, it has been deciphered how SARS-Co-V2 interacts and infects human kidney cells.
Within the EU project BRAVƎ, experts at Institute for Bioengineering of Catalonia (IBEC) combine cell therapy and bioengineering to design a biological device that recovers cardiac functionality in people with cardiovascular diseases.
Researchers at IBEC led by the ICREA Professor Núria Montserrat contribute to the EU project BRAVƎ, an initiative for cardiac regeneration that combines cell therapy and bioengineering to design a biological device capable of recovering cardiac functionality in people with coronary heart disease.
Researchers at the Institute of Bioengineering of Catalonia (IBEC) led by Professor ICREA Núria Montserrat are studying the role of the receptor ‘Angiotensin converting enzyme’ (ACE2), one of the pathways that the SARS-Co-V2 virus uses to enter our body.
To do this, experts use mini-kidneys, as well as other cell cultures such as cardiac organoids. The goal is to exploit these mini-organs to better understand how the virus works.
The Bacterial Infections: Antimicrobial Therapies group at IBEC, led by Eduard Torrents, has developed a system capable of investigating how pathogens adapt to oxygen changes.
Using this technique, they have discovered that bacteria E. coli and Pseudomonas aeruginosa can adapt to environmental changes through different mechanisms, which opens the door to better knowledge and treatment of infections.
A group from the Institute for Bioengineering of Catalonia (IBEC) led by Daniel Navajas contributes to an operation designed to repair the heart tissue of a 70-year-old patient who had suffered a heart attack. This was made possible by the creation of a bioimplant enriched with stem cells. The operation is the result of the joint work of scientists, doctors and engineers over more than ten years.
IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.
Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.